Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Nov 2014 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets

Fisher, F.M. et al. Gastroenterology

Nov 2009 | FROM EXTERNAL EXPERTS

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects

Xu, J. et al. American Journal of Physiology. Endocrinology and Metabolism

Feb 2007 | FROM EXTERNAL EXPERTS

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21

Kharitonenkov, A. et al. Endocrinology

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline